Skip to main content

Table 1 Overview of newly defined TPPs and TCPs

From: New developments in anti-malarial target candidate and product profiles

Profile

Intended use

TPP-1

Case management; treatment of acute uncomplicated malaria in children or adults. Uses a combination of two or more molecules with TCP-1 activity, plus TCP-5 for reducing transmission and TCP-3 for relapse prevention, when such molecules become available

For severe malaria, a parenteral formulation of a single fast-acting TCP-1 would be appropriate

TPP-2

Chemoprotection: given to subjects migrating into areas of high endemicity, or during epidemics. Uses a combination of TCP-4 activity, potentially with TCP-1 support for emerging infections

TCP-1

Molecules that clear asexual blood-stage parasitemia

TCP-2

(profile retired, see body of text)

TCP-3

Molecules with activity against hypnozoites (mainly P. vivax)

TCP-4

Molecules with activity against hepatic schizonts

TCP-5

Molecules that block transmission (targeting parasite gametocytes)

TCP-6

Molecules that block transmission by targeting the insect vector (endectocides)